Biocon Opens First US Manufacturing Plant in New Jersey
Indian biopharmaceutical giant Biocon has taken a big step forward by launching its first manufacturing facility in the United States. The new plant, located in Cranbury, New Jersey, and run by Biocon’s subsidiary Biocon Generics, focuses on producing oral solid dosage medications. This US-FDA-approved site can churn out up to 2 billion tablets every year, making it a key boost for Biocon’s global operations.
Biocon picked up the facility from Eywa Pharma back in 2023 and poured over $30 million into upgrades to turn it into a cutting-edge setup. As the company explains, this move helps spread out its manufacturing across different locations, builds a stronger supply chain, and speeds up its worldwide growth. It’s all about getting essential therapies to patients faster and ensuring reliable supplies in the US market.
A handful of products are already hitting the market from this plant, with many more in the works. Kiran Mazumdar-Shaw, the Chairperson of Biocon Group, called it a game-changer. "Biocon’s first US FDA-approved formulations facility in New Jersey marks a new chapter in our journey of global expansion," she said. "More than a milestone, it is a reaffirmation of our purpose to serve patients wherever they are."
The inauguration happened on Wednesday, with New Jersey Governor Phil Murphy and other industry leaders joining the celebrations. Siddharth Mittal, Biocon’s CEO and Managing Director, added that the plant brings the company closer to US patients and partners. "This strategic investment lets us deliver high-quality medicines more efficiently," he noted. "It strengthens our supply chain resilience and helps expand access to affordable therapies around the world."
On the stock front, Biocon shares have climbed 7 percent in the last month, cutting their year-to-date losses to just 1 percent. The company’s first-quarter results for FY26 showed revenue and EBITDA missing estimates by 2 percent and 11 percent, mainly due to a dip in the generics business. Still, biosimilar sales grew 1 percent quarter-on-quarter, while generics and CRDMO segments jumped 6 percent and 11 percent year-on-year, respectively.
This expansion highlights Biocon’s push into the US biopharmaceutical market, promising better access to affordable drugs for millions.
Stay informed on all the latest news, real-time breaking news updates, and follow all the important headlines in world News on Latest NewsX. Follow us on social media Facebook, Twitter(X), Gettr and subscribe our Youtube Channel.
